pfizer announced it s starting its phase three trial for its lyme disease vaccine. this is big news. you see here the plan is to enroll about 6,000 participants. these will be people ages 5 and older. this study will be conducted in europe and the u.s. at up to 50 sites where lyme disease is endemic. that s the plan right now. currently, there is no lyme disease vaccine on the market here in the u.s. so victor, that s why there are people very excited about this. all right, jacqueline howard, thank you so much. absolutely. more on the fbi search of former president trump s home. what gop lawmakers and even trump s former vice president, mike pence, are saying about it. and d forgot where she was. ( buzzer ) you can always spot a first time gain flingsgs user. as a main street bank, pnc has helped over 7 million kids develop their passion for learning. and now we re providing 88 billion dollars
booster shots for all adults. cnn s chief medical correspondent dr. sanjay gupta joins us now. i know the cdc has to sign on still. this is a big deal. right. yeah. i mean, this is something that i think people have seen coming for some time based on what the data has been showing, which is basically that the vaccines continue to work really well, but over time, either because of just the passage of time or because of the delta strain in particular, the idea that the protection against people getting sick does seem to wane a bit. that s the issue here. started seeing some of this in israel and now pfizer presented a phase three trial, about 10,000 people, showing that that same sort of thing, that effectiveness waning against severe disease in particular. so authorization now from the fda, as you mentioned the cdc, i think that meeting is going to begin around noon today. we ll see if there is a formal
getting the full adult 30 microgram pfizer dose. for kids 5 to 11 it will be 10 micrograms. can you explain why are the doses based on age not weight considering, you know, a 12-year-old could be smaller than an 11-year-old. what we do know is that pfizer actually tested a few different doses before they settled on the 10 microgram dose used in the phase three trial. so what i conjecture is that the 10 microgram dose is what seemed to do the best in that age group. what would you advise parents do if their kid just turned 12, go with the 12 to 18? yes, definitely go with the 12 to 18 full 30 microgram dose of the vaccine. you heard in nick s piece, several schools are considering pulling back on their mask mandates, but community transmission is still considered high in almost 80% of counties in the u.s. does this worry you considering
shots. one thing i just want to say quickly, the vast majority of severe illness, hospitalization and death is still very much among the unvaccinated. boosters are important, but when we talk about the next few months, this is an unvaccinated problem primarily. i m glad you made that point. the data is so clear. just one more question on boosters as we move in that direction. pfizer announced its data really just off the charts. 95.6% efficacy against covid, this in a phase three trial. what s the significance of that? yeah. i think what this is showing basically is when they got this booster and by the way, i think we should call it a third shot for people who are immune compromised and didn t have a significant antibody response in the first place. a booster shot for people who have normal, not weakened immune systems, so just in terms of the terminology. what they did is basically studied 10,000 people. some of them got the booster in this case, some got a placebo.
population growth in america, they re also becoming key voting blocks in swing counties. joe biden becomes the first u.s. president to commemorate indigenous people s day, along side columbus day. we ll look at what this recognition means for native american communities. communitis we begin this hour with breaking news regarding a new treatment for covid-19. pharmaceutical giant merck announced today that they re asking the food and drug administration to authorize an emergency use authorization for its antiviral drug to treat covid-19. earlier this month, merck announced results from a phase three trial of their drug which found their drug reduced the chance that patients with covid-19 would be hospitalized by 50%. joining me now outside of